Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a non-standard combination of the oral or systemic antibiotic doxycycline and the topical skin protectant ointment Aquaphor. Doxycycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, used for treating various bacterial infections including respiratory tract infections, acne, Lyme disease, and others. Aquaphor is an over-the-counter topical ointment composed primarily of petrolatum (petroleum jelly), mineral oil, ceresin, lanolin alcohol, panthenol, glycerin, and bisabolol; it acts as a skin protectant and moisturizer but has no direct antimicrobial activity. There are no known fixed-dose pharmaceutical products combining these two agents; if used together in clinical practice (for example in dermatology), they would be applied separately—doxycycline systemically or orally for infection/inflammation control and Aquaphor topically for barrier protection or wound healing support[6][7][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on doxycycline + Aquaphor.